Glutathione metabolism in ferroptosis and cancer therapy
Cancer Letters · 2025-07 · 621 · 217697
DOI: 10.1016/j.canlet.2025.217697 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Letters, 2025-07. Verfasst von Xiangfei Xue und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Laboratory, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, 200030, China. Hauptthemen laut MEDLINE: Ferroptosis, Neoplasms, Glutathione. Die Arbeit wurde bisher 165-mal zitiert (Crossref) und nennt 191 Literaturangaben.
Abstract (Originalsprache)
Glutathione (GSH), a non-enzymatic antioxidant in mammalian cells, plays an essential role in maintaining redox balance, mitigating oxidative stress, and preserving cellular homeostasis. Beyond its well-established function in detoxifying reactive oxygen species (ROS), GSH serves as a critical regulator of ferroptosis-an iron-dependent form of cell death marked by excessive lipid peroxidation. Serving as a cofactor for glutathione peroxidase 4 (GPX4), GSH catalyzes the conversion of lipid peroxides into non-toxic lipid alcohols, thereby preventing the accumulation of deleterious lipid oxidation products and halting the spread of oxidative damage. In cancer cells, upregulated GSH synthesis and GPX4 activity contribute to an enhanced antioxidant defense, countering oxidative stress provoked by increased metabolic demands and exposure to therapeutic agents such as chemotherapy, radiotherapy, and immunotherapy. This ability of cancer cells to modulate their ferroptosis susceptibility through GSH metabolism underscores its potential as a therapeutic target. Additionally, GSH influences several key oncogenic and tumor-suppressive signaling pathways, including NFE2L2/NRF2, TP53/p53, NF-κB, Hippo, and mTOR, which collectively regulate responses to oxidative stress, affect metabolic processes, and modulate sensitivity to ferroptosis in cancer cells. This review explores recent advancements in understanding GSH's multifaceted role in ferroptosis, emphasizing its implications for cancer biology and therapeutic interventions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Clinical Laboratory, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, 200030, China.
- College of Health Science and Technology, Shanghai Jiao Tong University School of Medicine, 200025, China.
- Department of Clinical Laboratory, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, 200030, China; Shanghai Institute of Thoracic Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong Universit…
- Department of Surgery, UT Southwestern Medical Center, Dallas, 75390, USA.
- Department of Surgery, UT Southwestern Medical Center, Dallas, 75390, USA. Electronic address: daolin.tang@utsouthwestern.edu.
Zitieren
APA
Xue, X., Wang, M., Cui, J., Yang, M., Ma, L., Kang, R., Tang, D., & Wang, J. (2025). Glutathione metabolism in ferroptosis and cancer therapy. Cancer Letters, 621, 217697. https://doi.org/10.1016/j.canlet.2025.217697
Vancouver
Xue X, Wang M, Cui J, Yang M, Ma L, Kang R, et al. Glutathione metabolism in ferroptosis and cancer therapy. Cancer Letters. 2025;621:217697. doi:10.1016/j.canlet.2025.217697
BibTeX
@article{Xue2025,
author = {Xue, Xiangfei and Wang, Manyuan and Cui, Jiangtao and Yang, Minying and Ma, Lifang and Kang, Rui and Tang, Daolin and Wang, Jiayi},
title = {Glutathione metabolism in ferroptosis and cancer therapy},
journal = {Cancer Letters},
year = {2025},
volume = {621},
pages = {217697},
doi = {10.1016/j.canlet.2025.217697}
}
EUVIMED